+34 679 490 537info@nanbiosis.com

JUMISC

JUMISC

III Conference on the Disclosure of Biomedical and Experimental Sciences

The III Conference for the Disclosure of Biomedical and Experimental Sciences will take place at the Center for Minimally Invasive Surgery Jesús Usón of Cáceres, on December 5, 2019. It will be attended by Francisco Miguel Sanchez Margallo, Deputy Scientific Director of NANBIOSIS and Beatriz Moreno Lobato, Scientific Director of Unit 19 of NANBIOSIS

FREE ACTIVITY – Requires prior registration until full capacity is reached

Pre- registration: https://www.ccmijesususon.com/formacion/preinscripcion/1173/

Program:

Read More

CCMIJU: Online Course on INTRODUCTION TO RESEARCH AND LABORATORY TECHNIQUES IN BIOCIENCES

During de dates Nov. 18 -30, 2019 will take place de course on line on Introduction to Research and Laboratory Techniques in Biociences, under the direction of NANBIOSIS U14 Cell Therapy Unit led by Javier García Casado Scientific Director of the Unit and Francisco M. Sánchez Margallo Scientific Director of CCMIJU and Deputy Scientific Director of NANBIOSIS.

For further information: Online Course on INTRODUCTION TO RESEARCH AND LABORATORY TECHNIQUES IN BIOCIENCES

Read More

“Minimal invasion, maximum innovation”

“Minimal invasion, maximum innovation” is a repot by Spanish TV about the Minimal Invasion Surgery Center, Jesús Usón, partner of NANBIOSIS.

“The unique capabilities of the Center from its animal farm to its surgical infrastructure allow the evaluation and validation of new technology such as medical devices, new biomaterials, new pharmacological therapies, before being used in human patients” explains Francisco Miguel Sanchez Margallo, Sciencitific Director of the Center and Deputy Scientific Director of NANBIOSIS- ICTS.

Verónica Crisóstomo, Scientific Director of NANBIOSIS Unit 24 of Medical imaging explains a current project that studies how to reduce the damage caused by a heart attack with stem cell-based treatment

The report can be seen heer:

http://www.rtve.es/m/alacarta/videos/lab24/lab24-reportaje-minima-invasion-maxima-innovacion/5425735/

Read More

Scientific breakthrough against the problems of advanced age in fertility.

Researchers of CCMIJU. led by Javier G. Casado, Scientific Director of NANBIOSIS U14 Cell Therapy, are coauthors of the article “Extracellular vesicles derived from endometrial human mesenchymal stem cells enhance embryo yield and quality in an aged murine model” published by. Biology of Reproduction,

The study of the beneficial effect of endometrial stem cell exosomes on embryonic quality has been developed in NANBIOSIS U14 and in collaboration with U22 and U23

Advanced age is a risk factor undermining women’s fertility. Hence, the optimization of assisted reproduction techniques is an interdisciplinary challenge that requires the improvement of in vitro culture systems. Here, we hypothesize that supplementation of embryo culture medium with extracellular vesicles from endometrial-derived mesenchymal stem cells (EV-endMSCs) may have a positive impact on the embryo competence of aged oocytes. In this work, 24 weeks old B6D2 female mice were used as egg donors and in vitro fertilization assays were performed using males from the same strain (8–12 weeks); the presumptive zygotes were incubated in the presence of 0, 10, 20, 40, or 80 μg/ml of EV-endMSCs. The results from the proteomic analysis of EV-endMSCs.

In summary, the supplementation of embryo culture medium with extracellular vesicles from endometrialderived mesenchymal stem cells increases the quality of aged embryos.

Read More

Laparoscopic surgery in the uterus retrieval procedure during uterine transplantation

Researchers of NANBIOSIS units at JUMISC have recently published the results of an study that highlights the promising application of laparoscopy for graft procurement surgery in uterine transplantation from living donors for absolute uterine infertility treatment. Laparoscopy seems to be a safe, time saving, useful and technically feasible surgical procedure for uterus extraction, with the additional benefits of minimally invasive surgery. It was also demonstrated that after a successful uterine transplant, pregnancy can be achieved by combining laparoscopy for uterine retrieval and microsurgery for vascular anastomosis. With the increasing success rate of human uterus transplantation trials from living donors, it is very probable that laparoscopic graft extraction will soon become a reality in the transplantation field. However, uterus transplantation will remain as a clinical experimental procedure until sufficient experience is achieved.

The resarch has been executed by using the Unique Scientific and Technical Infrastructure (ICTS) “NANBIOSIS.”

Article of reference:

Francisco Miguel Sánchez-Margallo,  Belén Moreno-Naranjo, María del Mar Pérez-López, Elena Abellán, José Antonio Domínguez-Arroyo, José Mijares &  Ignacio Santiago Álvarez. Laparoscopic uterine graft procurement and surgical autotransplantation in ovine model Scientific Reports 9, Article number: 8095 (2019) 

Read More

DEVELOPING A SENSOR FRAMEWORK FOR MINIMALLY INVASIVE SURGERY

Francisco Miguel Sánchez Margallo, Scientific Director of the Minimally Invasive Surgery Center ‘Jesús Usón’ and Deputy Director of NANBIOSIS, leads, together with Thomas Malone, of the Massachusetts Institute of Technology (MIT), in the United States, the project selected by the MIT program -Spain ‘La Caixa’ Foundation Seed Fund “Developint a sensor framework for minimally invasive surgery”.

The project seeks to develop a system of sensors to analyze health parameters of the surgeon, such as his physiological and ergonomic state, as well as the interaction between this and the patient during surgery. It is a disruptive research project on sensors to improve the health of the surgeon and the quality of surgery. NANBIOSIS units at JUMISC will play an important role in the development of the project.

This program was born with the aim of promoting the interrelation between Spanish research groups of excellence and those of MIT. The initiative aims to generate synergies and facilitate collaboration in international projects with a pioneering entity at the international level such as MIT.

The collaboration with MIT brings great value to Spanish research, since it is one of the best international research institutions. Among the professors about 80 Nobel prizes are counted, and its students have promoted more than 30,000 companies.

Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSISSeveral units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

Read More

Polymers and medical applications: Success Cases of Preclinical Research

Next May 10, a conference on “Polymers and medical applications” will be held in Vizcaya, with the participation of NANBIOSIS Deputy Director, and JUMISC Scientific Director Dr. Francisco Miguel Sánchez Margallo, as guest speaker, who will give the lecture “Preclinical Research: Success Cases

The event will count also with the expertise of Dr. Miguel Angel Martínez, Scientific Director of NANBIOSIS U13 Tissue & Scaffold Characterization Unittalking about “Modeling and simulation in biomedical applications

Other topics that will be discussed at the Conference will be Hydrogels, Nanogels and Nanoparticles for Controlled Release of Bioactive Substances,
The Microfluidics as a Tool for the Development of “Organ-on-a-chip and the Use of Liquid Silicone in Devices for Cell Growth.

Leartiker is a team of researchers dedicated to R+D+I, specialized in Polymer Technology and belonging to the Basque Science and Technology Network (RVCTI).

Registration is free until full capacity is reached.

More information here.

Read More

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity.

Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article.

Article of reference:

Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad, Helena Martín, Claudia Báez,Virginia Blanco,Verónica Crisóstomo and Javier García Casado “Identification of very early inflammatory markers in a porcine myocardial infarction model” BMC Veterinary Research 2019-15:91

Read More

Meshes in a mess: Mesenchymal stem cell-based therapies for soft tissue reinforcement

Unit 14 of Nanbiosis of Cell Therapy, led by Javier García Casado, has published a review on advances in the development of surgical meshes combined with stem cells. The work of the Nanbiosis team has been published in the prestigious journal “Acta Biomaterialia”

Read More